Trials / Withdrawn
WithdrawnNCT02735876
A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
A Randomized, Multicenter, Open Label, Phase 3 Study of Acalabrutinib (ACP-196) in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib Alone in Subjects With Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL)
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Acerta Pharma BV · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is evaluating the efficacy of acalabrutinib in combination with rituximab (Arm 1) versus ibrutinib (Arm 2) versus acalabrutinib (Arm 3) for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | acalabrutinib | |
| DRUG | ibrutinib | |
| DRUG | rituximab |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2020-06-01
- First posted
- 2016-04-13
- Last updated
- 2016-05-13
Source: ClinicalTrials.gov record NCT02735876. Inclusion in this directory is not an endorsement.